NORDIC PHARMA LIMITED

• ◆

  1 PSC ceased in last 24 months

  Significant control changed hands — see the Ownership section.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +10.8%

  £17,712,186 → £19,624,379

• Cash

  +257.9%

  £1,444,787 → £5,170,553

  highest in 3 filed years

• Net assets

  +133.8%

  £5,779,992 → £13,513,723

• Employees

  -3.4%

  29 → 28

• Operating profit

  +602.2%

  £242,772 → £1,704,810

• Profit before tax

  +15,291.9%

  £41,646 → £6,410,101

• Wages

  -15.4%

  £2,269,006 → £1,920,293

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. NORDIC PHARMA LIMITED 2002-05-07 → present
2. NORDIC PHARMACEUTICALS LIMITED 1980-04-02 → 2002-05-07

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

Kirk Rice LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“At the time of approving the financial statements, the directors have a reasonable expectation that the group has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.”

Group structure

1. NORDIC PHARMA LIMITED · parent
   1. Draupnir Holdings Ltd 100% · England
   2. ParaPharm Development Ltd 100% · England
   3. Altacor Ltd 100% · England
   4. Altacor GmbH 100% · Germany

Significant events

• “The increase in profit after tax is primarily due to the sale of Transdermal Limited outside of the Nordic Pharma UK Group.”
• “During the year, Nordic Pharma Limited ceased control over Parapharm Development, SL (registered in Spain) due to Parapharm Development, SL being liquidated.”
• “Also in the year, 100% of the shares held in Transdermal were sold.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.